Asia On The Move: Takeda Hires Bayer Executive As Global Manufacturing Officer
This article was originally published in PharmAsia News
Executive Summary
Takeda names its first global manufacturing officer, while Daiichi Sankyo’s president leaves after the sale of Ranbaxy to India’s Sun Pharmaceuticals. Executive changes also happened at Otsuka, Meiji Seika, Chugai, and there are new general counsels at AstraZeneca and Agilent in China.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.